Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas
- PMID: 20116285
- DOI: 10.1016/j.jvir.2009.11.014
Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas
Abstract
Purpose: To assess the diagnostic value of gadoxetic acid-enhanced magnetic resonance (MR) imaging in follow-up of patients with hepatocellular carcinomas (HCCs) who were treated with radiofrequency (RF) ablation and to compare it with that of four-phase multi-detector row computed tomography (CT).
Materials and methods: From July 2007 to May 2008, 36 patients (43 HCCs) were enrolled who were treated with RF ablation (tumor size, 20-47 mm; mean, 24.5 mm) and underwent gadoxetic acid-enhanced MR imaging and four-phase (precontrast, arterial, portal venous, and equilibrium) multidetector CT for follow-up. Two radiologists independently reviewed these images, and conspicuity of tumor margins and detection of residual or recurrent tumor were assessed on a five-point scale with receiver operating characteristic (ROC) curve analysis. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were evaluated.
Results: The mean conspicuity value of tumor margins was significantly higher on MR imaging than on multidetector CT (P < .001). The degree of differentiation between residual/recurrent tumor and hyperemia was significantly greater on MR imaging (P < .001). The mean area under the ROC curve was significantly higher with MR imaging (P = .015), as were sensitivity, specificity, PPV, NPV, and accuracy of detection rate (mean, 100%, 96.2%, 82.4%, 100%, and 96.7%, respectively, vs 41.7%, 56.8%, 13.5%, 85.7%, and 54.7% for multidetector CT). The interobserver agreement rate for MR imaging was higher (0.919) than for multidetector CT (0.672; P < .05).
Conclusions: Diagnostic accuracy, conspicuity of tumor margins, and detection rate of residual or recurrent tumor were found to be better with gadoxetic acid-enhanced MR imaging than with four-phase multidetector CT.
Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.Invest Radiol. 2010 Feb;45(2):96-103. doi: 10.1097/RLI.0b013e3181c5faf7. Invest Radiol. 2010. PMID: 20057319
-
Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.AJR Am J Roentgenol. 2009 Jun;192(6):1675-81. doi: 10.2214/AJR.08.1262. AJR Am J Roentgenol. 2009. PMID: 19457834
-
Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging.J Magn Reson Imaging. 2011 Jul;34(1):69-78. doi: 10.1002/jmri.22588. Epub 2011 May 19. J Magn Reson Imaging. 2011. PMID: 21598343
-
Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis.Abdom Radiol (NY). 2016 Oct;41(10):1960-72. doi: 10.1007/s00261-016-0807-7. Abdom Radiol (NY). 2016. PMID: 27318936 Free PMC article.
-
Diagnosis of hepatocellular carcinoma: newer radiological tools.Semin Oncol. 2012 Aug;39(4):399-409. doi: 10.1053/j.seminoncol.2012.05.010. Semin Oncol. 2012. PMID: 22846858 Review.
Cited by
-
Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography.J Med Ultrason (2001). 2018 Jul;45(3):405-415. doi: 10.1007/s10396-018-0861-6. Epub 2018 Jan 23. J Med Ultrason (2001). 2018. PMID: 29362966
-
Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment.JGH Open. 2023 Apr 3;7(4):249-260. doi: 10.1002/jgh3.12879. eCollection 2023 Apr. JGH Open. 2023. PMID: 37125252 Free PMC article. Review.
-
Role of gadoxetic acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment.World J Gastroenterol. 2022 Jul 14;28(26):3116-3131. doi: 10.3748/wjg.v28.i26.3116. World J Gastroenterol. 2022. PMID: 36051340 Free PMC article. Review.
-
[Diagnosis of and therapy for hepatocellular carcinoma].Z Gastroenterol. 2013 Nov;51(11):1269-326. doi: 10.1055/s-0033-1355841. Epub 2013 Nov 15. Z Gastroenterol. 2013. PMID: 24243572 Free PMC article.
-
Interreader Reliability of Liver Imaging Reporting and Data System Treatment Response: A Systematic Review and Meta-Analysis.Diagnostics (Basel). 2021 Feb 4;11(2):237. doi: 10.3390/diagnostics11020237. Diagnostics (Basel). 2021. PMID: 33557040 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical